1. 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. (9th November 2020) Authors: Middleton, Mark; Aroldi, Francesca; Sacco, Joseph; Milhem, Mohammed; Curti, Brendan; MBioeth, Ari VanderWalde; Baum, Scott; Samson, Adel; Pavlick, Anna; Chesney, Jason; Niu, Jiaxin; Rhodes, Terence; Bowles, Tawnya; Conry, Robert; Olsson-Brown, Anna; Laux, Douglas Earl; Kaufman, Howard; Bommareddy... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Issue 3 (15th November 2016) Authors: Samson, Adel; Bentham, Matthew J; Scott, Karen; Nuovo, Gerard; Bloy, Abigail; Appleton, Elizabeth; Adair, Robert A; Dave, Rajiv; Peckham-Cooper, Adam; Toogood, Giles; Nagamori, Seishi; Coffey, Matthew; Vile, Richard; Harrington, Kevin; Selby, Peter; Errington-Mais, Fiona; Melcher, Alan; Griffin, ... Journal: Gut Issue: Volume 67:Issue 3(2018) Page Start: 562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Issue 1 (1st July 2019) Authors: Müller, Louise M. E.; Holmes, Matthew; Michael, Joanne L.; Scott, Gina B.; West, Emma J.; Scott, Karen J.; Parrish, Christopher; Hall, Kathryn; Stäble, Sina; Jennings, Victoria A.; Cullen, Matthew; McConnell, Stewart; Langton, Catherine; Tidswell, Emma L.; Shafren, Darren; Samson, Adel; Harringto... Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Issue 3 (19th March 2021) Authors: Müller, Louise M E; Migneco, Gemma; Scott, Gina B; Down, Jenny; King, Sancha; Askar, Basem; Jennings, Victoria; Oyajobi, Babatunde; Scott, Karen; West, Emma; Ralph, Christy; Samson, Adel; Ilett, Elizabeth J; Muthana, Munitta; Coffey, Matt; Melcher, Alan; Parrish, Christopher; Cook, Gordon; Lawson... Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS. (9th November 2020) Authors: Kendall, Jessica; Chalmers, Anthony; McBain, Catherine; Melcher, Alan; Samson, Adel; Phillip, Rachel; Brown, Sarah; Short, Susan Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immunotherapies for hepatocellular carcinoma. (24th December 2021) Authors: Liu, Justin K. H.; Irvine, Andrew F.; Jones, Rebecca L.; Samson, Adel Journal: Cancer medicine Issue: Volume 11:Number 3(2022) Page Start: 571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗